





الجامعة الإسلامية العالمية ماليزيا

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

يُونُسُ بَرَسِيَّتِي اسْتَأْذَرَ ابْتِارَ اِيْخْسَا مَلِيْسِيَا

IN-VIVO ANTIPARASITIC ASSESSMENT OF ALLICIN AGAINST THE GROWTH AND SURVIVAL OF HAEMOFLAGELLATE, *Trypanosoma evansi*



Asst. Prof. Dr. Mohd Shukri Bin Baba

*Department of Biomedical Science, Kulliyyah of Allied Health Sciences,
International Islamic University Malaysia*

INTRODUCTION



Trypanosoma evansi

- Species of *Trypanosoma* → Trypanosomiasis clusters
- Trypanosomiasis = vector-borne parasitic diseases (sleeping sickness, chagas disease and surra disease)
- *T. evansi* : haemoflagellated protozoa in mammals → surra disease (human zoonotic disease)
- 1st discovered (1880) by Griffith Evans in Punjab, India
- Malaysia : 1903 → cow & sheep due to livestock migration



VECTORS OF TRYPANOSOMIASIS



Tabanus striatus



Hirudo medicinalis




Glossina morsitans



Desmondus rotundus

ALLICIN

- Chemically : 2-propenyl-1-dialyl tiosulfinate ($C_6H_{10}OS_2$)
- Naturally, not part of garlic compound (*Allium sativum*)
- Crushed/damaged garlic $\rightarrow$ AA (allin) interacted with catalytic enzyme (allinase) $\rightarrow$ allicin



ALLICIN : THE TESTIMONIAL


- As **anti-inflammatory** and **antibacterial** agents in China since more than a century (Cavalitto et al. 1944)
- Natural **insecticide** & **fungicide** (Cavalitto et al. 1944)
- *In-vivo* & *in-vitro* **anti-leishmanial** activity against *Leishmania donovani* in mice (Nok et al. 1996)
- Inhibit the growth of *Candida albicans*, *Giardia lamblia* and *Entamoeba histolytica* (Ankry et al. 1997)
- Antibacterial property with very low IC₅₀ against *E. coli* EPEC strain (Ankry & Mirelman, 1999)
- Promising **anti-hypertensive** and **anti-asthmatic** effects on infants and young ages hosts (Rabinkov et al. 1998)

MATERIALS & METHODS



FLOW CHART

T. evansi stock



T. evansi administered i.p.
(5×10^3 *T. evansi* / mice)



0.1 mL 15 μ g/mL allisin-dH₂O
solution administered orally



Giemsa blood
slide for
inhibition rate
evaluation



Blood slide for
electron
microscopic
observation



Physical
observation of
symptoms and
mice survival



Blood
biochemistry
and renal
function tests



Vital organ
histology for
toxicity
assessment





EXPERIMENTAL DESIGN

GROUP	REGIME	DESCRIPTION	DOSAGE
TREATMENT	PREVENTIVE	7 days pre-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
		5 days pre-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
		3 days pre-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
	CONCURRENT	2 hours post-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
	CURATIVE	3 days post-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
		5 days post-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
		7 days post-infection	0.1 mL 15 µg/mL allisin-dH ₂ O
CONTROL	POSITIVE	Berenil (Sigma-Aldrich KL)	0.01 mL 3.5 mg/kg bw
	NEGATIVE	0.9 % Normal Saline	0.1 mL 0.9 normal saline
	LETHAL INFECTION	Infection without treatment	5 × 10 ³ parasites / mice (i.p.)



PARASITE ADMINISTRATION & ANIMAL TAGGING



GIEMSA STAINING & MICROSCOPIC OBSERVATION




BIOCHEMICAL TEST AND ORGAN HISTOLOGY





RESULTS & DISCUSSIONS



MICE SURVIVAL TIME





PARASITE SURVIVAL IN PRO1 GROUP: ON 100th DAY




Giemsa thin blood smear of the mice from PRE7 group taken on day 100 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30) (B)

PARASITE SURVIVAL IN PRO1 GROUP: ON 115th DAY




Giemsa thin blood smear of the mice from PRE7 group taken on day 115 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30) (B)

PARASITE SURVIVAL IN PRO1 GROUP: ON 130th DAY




DAY 130




Giemsa thin blood smear of the mice from PRE7 group taken on day 130 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30) (B)

PARASITE SURVIVAL IN PRO1 GROUP: ON 145th DAY




DAY 145




Giemsa thin blood smear of the mice from PRE7 group taken on day 145 as observed under x100 magnification of light microscope (A) and x4000 magnification of SEM (Phillips XL30) (B)



PARASITE SURVIVAL IN PRO1 GROUP: ON 160th DAY



DAY 160




Giemsa thin blood smear of the mice from PRE7 group taken on day 160 as observed under x100 magnification of light microscope (A) and x5010 magnification of SEM (Leo 1450VP) (B)

PARASITE SURVIVAL IN PRO1 GROUP: ON 175th DAY**DAY 175**



Giemsa thin blood smear of the mice from PRE7 group taken on day 175 as observed under x100 magnification of light microscope (A) and x4620 magnification of SEM (Leo 1450VP) (B)

GIEMSA BLOOD FILMS





Reemerged of *T. evansi* which survived in PRE7 group mice on day 180 (A) and day 183 (B) due to the action of 'variable surface glycoprotein (VSG) stochastic genetic modification' as observed under x100 magnification of light microscope.

ELECTRON MICROSCOPIC OBSERVATION




Reemerged of *T. evansi* which survived in PRE7 group mice on day 180 (A) and day 183 (B) due to the action of 'variable surface glycoprotein (VSA) stochastic genetic modification' as respectively observed under x1600 (A) and x2300 (B) magnification by SEM (Leo 1450VP).



PARASITE GROWTH IN POSITIVE CONTROL GROUP




The growth of *T. evansi* in POS group mice taken on 1 hour (left) and 2 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and x5000 magnification of SEM electron microscope (Phillips XL30) (A2 & B2)




PARASITE GROWTH IN POSITIVE CONTROL GROUP




The growth of *T. evansi* in POS group mice taken on 3 hours (left) and 4 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and respectively under x3000 (A2) and x2000 (B2) magnification of SEM electron microscope (Phillips XL30)





PARASITE GROWTH IN POSITIVE CONTROL GROUP



The growth of *T. evansi* in POS group mice taken on 5 hours (left) and 6 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and x5000 magnification of SEM electron microscope (Phillips XL30) (A2 & B2)



ALLICIN vs BERENIL



Scanning electron micrograph (SEM) showed the morphological changes of *T. evansi* in PRE7 mice on 175th day post infection (A) (Leo 1450VP) and in POS mice at 6th hours post treatment (0.01 mL 3.5 mg/kg bw Berenil) (B) (Phillips XL30)

BIOCHEMICAL TESTS FOR TOXICITY ASSESSMENT






Test	TA	TB	TC	TD	CN	CI	NR	Unit
ALT	41.81 ± 2.14	45.20 ± 1.13	67.57 ± 2.91	90.03 ± 2.02	41.03 ± 3.91	44.83 ± 1.11	40 – 93	IU/L
AST	133.13 ± 2.04	125.93 ± 2.12	167.76 ± 2.27	187.01 ± 2.09	111.62 ± 1.19	134.43 ± 4.01	92 – 206	IU/L
ALP	62.76 ± 2.33	59.4 ± 2.97	69.2 ± 2.90	68.03 ± 2.10	61.46 ± 2.46	58.32 ± 2.97	54 – 115	IU/L
STP	6.12 ± 2.32	7.21 ± 3.81	7.93 ± 2.01	8.83 ± 3.90	6.40 ± 1.01	6.80 ± 3.06	5.8 – 9.5	g/dL




TA	: Sub-acute regime – Daily treatment (28 days)
TB	: Sub-acute regime – Daily treatment (28 days) 2 hours post-infection
TC	: Sub-chronic regime – Daily treatment (90 days)
TD	: Sub-chronic regime – Daily treatment (90 days) 2 hours post-infection
CN	: Control regime – Normal mice without infection and treatment
CI	: Control regime – Infected mice on D0
ALT	: Alanine aminotransferase
AST	: Aspartate transaminase
ALP	: Alkaline phosphatase
STP	: Serum total protein

ORGAN HISTOLOGY FOR TOXICITY ASSESSMENT



Treatment
(Acute)



Treatment
(Sub-acute)



Control



KIDNEY

LIVER

SPLEEN

DISCUSSIONS




DISCUSSION

- Allicin exhibited very significant and promising anti-parasitic activity against the infection of surra disease.
- Allicin could prolong the survival of infected host and leave no undesired toxicity effects towards the blood enzymes level and vital organs.
- New wave of infection → host is susceptible to infection and suffer with chronic infection (Cavalitto et al. 1944)
- Stochastic genetic modification of VSG is still the best weapon for trypanosome survival (Nok et al. 1996).
- The action of tiosulfinates group in allicin molecule towards – thiol group of parasite enzymes which was crucial for parasite proliferation (Ankry & Mirelman, 1999).

ABSOLUTE HYPOTHESIS

EAT GARLIC..!

NO HARM TO EAT AS MUCH AS YOU CAN



ABSOLUTE HYPOTHESIS



REFERENCES



- Agarwal, M., Walia, S., Dhingra, S., Khambay B.P. 2001. Insect growth inhibition, antifeedant and antifungal activity of compounds isolated from *Zingiber officinale* Roscoe (ginger) rhizomes. *Pest Manage. Sci.* 57: 289-300.
- Ankri, S. & Mirelman, D. 1999. Antimicrobial properties of allicin from garlic. *Microbes Infect.* 1, 125-129.
- Ankri, S., Miron, T., Rabinikov, A., Wilchek, M. & Mirelman, D. 1997. Allicin from garlic strongly inhibits cysteine proteases and cytopathic effects of *Entamoeba histolytica*. *Antimicrob Agents Chemother.* 41, pp. 2286–2288.
- Chen, H.C., Chang, M.D. & Chang, T.J. 1985. Antibacterial properties of some spice plants before and after heat treatment. 18: 190-195.
- Cox, S.D., Mann, J.L., Bell, J.E. & Warmington, S.G. 2000. The mode of antimicrobial action of the essential oil of *Melaleuca alternifolia* (tea tree oil). *Journal of Applied Microbiology* 88, 170–175.
- Denise, C.A., Fabio, D.A., Alejandro, M.K. & Silvia, R.U. 2004. Antileishmanial activity of the terene Nerolidol. Departamento de Parasitologia, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Brazil.

- Denyer, C.V., Jackson, P., Loakes, D.M., Ellis M.R. & Young, D.A. 1994. Isolation of antirhinoviral sesquiterpenes from ginger (*Zingiber officinale*). *J. Nat. Prod.* 57: 658-662.
- Goto, C., Kasuya, S., Koga, K., Ohtomo, H. & Kagei, N. 1990. Lethal efficacy of extract from *Zingiber officinale* (traditional Chinese medicine) or shogaol and gingerol in *Anisakis* larvae *in vitro*. *Parasitol. Res.* 76: 653-656.
- Nok, A.J., William, S. & Onyenekwe, P.C. 1996. *Allium sativum* : induced death of African trypanosomes. *Parasitol. Res.* 82: 634-637.
- Ogunlana, E.O., Hoeglund, S., Onawunmi, G. & Skoeld, O. 1987. Effects of lemongrass oil on the morphological characteristics and peptidoglycan synthesis of *Escherichia coli* cells. *Microbios*, 50, 43–59.
- Rabinkov, A., Wilchek, M. & Mirelman, D. 1998. The mode of action of allicin: Trapping of radicals and interaction with thiol containing proteins. *Biochem. Biophys. Acta* 1379, 233-244.
- Zainal-Abidin, B.A.H. 1992. Infections of *Trypanosoma evansi* in Malaysia. *Malays. Applied Biology* 10: 1-8.

THANK YOU



RATIONALE OF THE STUDY

Reliability of Berenil

- *T. evansi* strain from India & Indonesia are resistant
- Unaffordable → expensive in certain regions
- Wrong dosage & concentration → side effects

Economic Growth & Biotechnology Sector

- Biotechnology → Malaysian main focus in the next decade
- Garlic → consumable & easily manipulated herbal plant
- Surra disease → influenced productivity of the livestock

Current Issues of *T. evansi*

- Trans-host boundary : animal → human (Assam India 2008)
- Potential trans-continent zoonotic disease

‘Variable Surface Glycoprotein’ (VSG)


- Survival factor of *Trypanosoma* spp. in the infected host
- High density layer on the parasite cell membrane
- Contained 1×10^9 similar & uniformed glycoprotein molecules expressed by VSG-Trypanosome gene
- Protect the parasite from being identified/action of the host immune system
- Similar & uniformed glycoprotein molecule → only end region of ‘N-terminal loops’ structure (300-500 amino acid structures) can be identified by the host immune systems → specific antibody-antigen mechanisms

‘Variable Surface Glikoprotein’ (VSG) – cont.

- When the end region of `N-terminal loops' structure being identified by the host immune systems → VSG-stochastic genetic modification' of the parasite plays the role.
- VSG stochastic genetic modification = periodic changes of antigenic variation → the structures & characteristics of parasite cell membrane was modified whenever confronted with the host's specific immune system which may varies.
- Periodic changes of antigenic variation → changes in parasitemia waves → longer survival time of the parasite → chronic infection on host

Survival Pattern of the Trypanosomiasis Infected-Host Due to VSG-Stochastic Genetic Modification Phenomenon

Effectuation of the changes in host's specific immune system



Day of
Infection

Mechanism of Trypanosome VSG-stochastic genetic modification